












---

# BEIJING BENOCON PHARMACEUTICAL TECHNOLOGY CO., LTD.

- Product List


















## Respiratory

Product Name	CAS.NO	Dosage Form	Specs	ATC	Chemical Structure
Fluticasone Propionate	80474-14-2	Nasal Spray/Nebuliser Suspension/Inhalation Aerosol	USP/EP	ICS	
Fluticasone Furoate	397864-44-7	Nasal Spray/Inhalation Powder	In-house	ICS	
Budesonide	51333-22-3	Inhalation Powder/Nebuliser Suspension/Inhalation Aerosol	USP/EP	ICS	
Triamcinolone Acetonide	76-25-5	Inhalation Powder	USP/EP/CP	ICS	
Vilanterol	503068-34-6	Inhalation Powder	In-house	LABA	
Salmeterol Xinafoate	94749-08-3	Inhalation Powder	USP/EP	LABA	
Indacaterol Maleate	753498-25-8	Inhalation Powder	In-house	LABA	
Glycopyrronium Bromide	596-51-0	Inhalation Powder	USP/EP/CP	LAMA	
Umeclidinium Bromide	869113-09-7	Inhalation Powder	In-house	LAMA	
Levalbuterol Hydrochloride	50293-90-8	Inhalation Powder	USP	SABA	












**Any products listed above within the periods of patents shall be subject to R&D only.**

## CNS

Product Name	CAS.NO	Indication	Specs	Chemical Structure
Rasagiline	136236-51-6	Parkinson's disease	In-house	
Lumateperone	313368-91-1	Schizophrenia	In-house	
Lemborexant	1369764-02-2	Insomnia	In-house	
Mirogabalin	1138245-13-2	Peripheral nervous pain	In-house	
Levetiracetam	102767-28-2	Anti-epileptic	USP/EP/BP	
Levodopa	59-92-7	Parkinson's disease	USP/EP/BP	
Brivaracetam	357336-20-0	Epilepsia	In-house	
Carbidopa	28860-95-9	Parkinson' disease	USP/EP/BP	
Escitalopram Oxalate	219861-08-2	Antidepressant, Anxiolytic	USP/EP/BP	
Gabapentin	60142-96-3	Anticonvulsant	USP/EP/BP	
Safinamide	133865-89-1	Parkinson's disease	In-house	
Paroxetine hcl Anhydrous	78246-49-8	Antidepressant	USP/EP/BP	
Paroxetine hcl Hemihydrate	110429-35-1	Antidepressant	USP/EP/BP	
Caffeine Citrate	69-22-7	Migraines	USP/EP/BP	
Risperidone	106266-06-2	Schizophrenia	USP/EP/BP	

**Any products listed above within the periods of patents shall be subject to R&D only.**

## Others

Product Name	CAS.NO	Indication	Specs	Chemical Structure
Sitafloxacin Hydrate	163253-35-8	Broad-spectrum antibiotic	In-house	
Ticagrelor	274693-27-5	Platelet aggregation	In-house	
Sacubitril / Valsartan	936623-90-4	Chronic heart failure with decreased ejection fraction	In-house	
Obeticholic Acid	459789-99-2	Primary biliary cholangitis	In-house	
Delafloxacin	44252-91-2	Broad-spectrum antibiotic	In-house	
Baloxavir Marboxil	1985606-14-1	Influeza	In-house	
Benazepril Hydrochloride	86541-74-4	Hypertensive, congestive heart-failure	USP/EP/BP	
Tofacitinib Citrate	477600-75-2	Rheumatoid arthritis	In-house	
Baricitinib Phosphate	1187595-84-1	Rheumatoid arthritis	In-house	
Filgotinib	1206161-97-8	Rheumatoid arthritis	In-house	
Upadacitinib	1310726-60-3	Rheumatoid arthritis	In-house	

**Any products listed above within the periods of patents shall be subject to R&D only.**